Compassionate Use of Vonsetamig

Overview

Key facts that identify this study and show where it stands today.

What the study is about and why it is being run, in the researchers' own words.

Brief Summary: Provide Compassionate Use of Vonsetamig
Detailed Description: Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

The medical conditions and diseases this study investigates.

The treatments and procedures being evaluated in this study.

Who can join this study and the criteria used to decide.

Ages Eligible for Study: Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: No data available
Accepts Healthy Volunteers: No data available
Eligibility Criteria: Eligibility will be determined during the application review process.

How the study is designed and how its participant groups are organized.

No design

There is no design for this study.

The people to reach with questions about this study or how to join it.

Requests for compassionate use must be initiated by a treating physician. Physicians should contactContact

Managedaccessrequests@regeneron.com844-734-6643

Where the study is run and whether each site is currently recruiting.

No locations

There are no locations for this study.

The organizations and people involved in this study.

Other registered studies that closely resemble this one.

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
NCT05164250
Approved for marketingExpanded AccessUpdated Nov 10, 2025
Compassionate Use of Vidutolimod
NCT06063746
No longer availableExpanded AccessUpdated Jan 8, 2026
A Compassionate Use (CU) Program of Odronextamab
NCT05619367
AvailableExpanded AccessUpdated Dec 23, 2025
Compassionate Use of REGN-COV2 for the Treatment of COVID-19
NCT04617535
No longer availableExpanded AccessUpdated Oct 3, 2023
Compassionate Use of Pozelimab
NCT05232110
Approved for marketingExpanded AccessUpdated Nov 10, 2025
Compassionate Use of Evinacumab
NCT06500598
Approved for marketingExpanded AccessUpdated Oct 28, 2025